Ocugen, Inc.
NASDAQ:OCGNBiotechnology
Healthcare
$0.76 +2.46%
+$0.03 today
- Market cap
- $256.75M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
52W Low $0.90High $2.73
Volume 5.47M
Average 7.51M
Income Statement
Follow revenue through to earnings.
Revenue
$4.41M
FY 2025 · Annual
+8.8% YoYOperating Income
-$62.92M
FY 2025 · Annual
Net Income
-$67.85M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 2.49M | 6.04M | 4.06M | 4.41M |
| Cost of Revenue | 0 | 0 | 704K | 1.97M | 2.39M |
| Gross Profit | 0 | 2.49M | 5.33M | 2.09M | 2.02M |
| Gross Margin | — | 100.0% | 88.3% | 51.5% | 45.9% |
| Research & Development | 35.11M | 56.16M | 39.57M | 32.13M | 39.75M |
| Selling, General & Admin | 22.92M | 35.4M | 31.99M | 26.69M | 27.58M |
| Operating Expenses | 58.03M | 91.56M | 70.86M | 56.84M | 64.94M |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| EBITDA | (58.11M) | (86.32M) | (62.37M) | (52.09M) | (60.27M) |
| EBITDA Margin | — | -3469.6% | -1033.4% | -1284.5% | -1365.7% |
| Operating Income | (58.03M) | (89.07M) | (65.53M) | (54.76M) | (62.92M) |
| Operating Margin | — | -3580.0% | -1085.7% | -1350.4% | -1425.7% |
| Interest Income | 0 | 1.4M | 2.5M | 1.3M | 922K |
| Interest Expense | 79K | 0 | 0 | 0 | 5.19M |
| Other Income / Expenses | (389K) | 2.27M | 2.45M | 703K | (4.93M) |
| Income Before Tax | (58.42M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Pre-Tax Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| Income Tax Expense | (52K) | 0 | 0 | 0 | 0 |
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Net Margin | — | -3488.9% | -1045.0% | -1333.0% | -1537.4% |
| EPS (Basic) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| EPS (Diluted) | (0.30) | (0.40) | (0.26) | (0.20) | (0.23) |
| 195.01M | 214.6M | 244.33M | 271M | 300.17M | |
| 195.01M | 214.6M | 244.33M | 271M | 300.17M |
OCGN Earnings Waterfall · TTM
NASDAQ:OCGN · Revenue to Net Income
Key Ratios
EPS$-0.23
Gross Margin100.0%
Net Margin1426.3%
P/E Ratio-6.1
P/S Ratio-329.3
Analysis
$4.5M of revenue converted into -$71.7M of net income for the selected period. Gross margin is 100.0% and net margin is 1426.3%, showing how much revenue survives after costs and taxes. EPS is $-0.23, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| DEFA14A | DEFA14A filing | Nov 6, 2026 | |
| DEFA14A | DEFA14A filing | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| 8-K | Current report | Nov 4, 2026 |
How much revenue does OCGN generate?
Ocugen, Inc. (OCGN) reported $4.41M of revenue in fiscal 2025.
Is OCGN profitable?
Ocugen, Inc. (OCGN) reported -$67.85M of net income, with a net margin of -1537.4%.
Continue the stock analysis
Jump to another research area for this company.